Prostate motion during radiotherapy of prostate cancer patients with and without application of a hydrogel spacer: a comparative study

Radiation Oncology

Thomas Eade¹  Paul J. Keall⁴  Jin A. Ng⁴  Emma Colvill⁴  Ramandeep Kaur²  David I. Thwaites³  Jeremy T. Booth³  Andrew Kneebone¹  Prabhjot Juneja³ 

[1] Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney 2065, NSW, Australia;5/161A Willoughby Road, Naremburn 2065, NSW, Australia;Institute of Medical Physics, School of Physics, University of Sydney, Sydney 2006, NSW, Australia;Radiation Physics Laboratory, School of Medicine, University of Sydney, Sydney 2006, NSW, Australia

关键词: Hydrogel spacer;    Intrafraction motion;    Radiotherapy;    Prostate cancer;   

Others  :  1232604
DOI  :  10.1186/s13014-015-0526-1

 received in 2015-07-10, accepted in 2015-10-19,  发布年份 2015

【 摘 要 】

Background and purpose

The use of a tissue expander (hydrogel) for sparing of the rectum from increased irradiation during prostate radiotherapy is becoming popular. The goal of this study is to investigate the effect of a tissue expander (hydrogel) on the intrafraction prostate motion during radiotherapy.

Methods and material

Real time prostate motion was analysed for 26 patients and 742 fractions; 12 patients with and 14 patients without hydrogel (SpaceOAR™). The intra-fraction motion was quantified and compared between the two groups.

Results

The average (±standard deviation) of the mean motion during the treatment for patients with and without hydrogel was 1.5 (±0.8 mm) and 1.1 (±0.9 mm) respectively (p < 0.05). The average time of motion >3 mm for patients with and without hydrogel was 7.7 % (±1.1 %) and 4.5 % (±0.9 %) respectively (p > 0.05). The hydrogel age, fraction number and treatment time were found to have no effect (R ²  < 0.05) on the prostate motion.

Conclusions

Differences in intrafraction motion in patients with hydrogel and without hydrogel were within measurement uncertainty (<1 mm). This result confirms that the addition of a spacer does not negate the need for intrafraction motion management if clinically indicated.

【 授权许可】

   
2015 Juneja et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70(4):1146-50.
• [2]Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM et al.. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys. 2013; 87(5):932-8.
• [3]Prada PJ, Fernández J, Martinez AA, De La Rua A, Gonzalez JM, Fernandez JM et al.. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys. 2007; 69(1):95-102.
• [4]Noyes WR, Hosford CC, Schultz SE. Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys. 2012; 82(5):1918-22.
• [5]King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S et al.. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013; 109(2):217-21.
• [6]Engels B, Soete G, Verellen D, Storme G. Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int J Radiat Oncol Biol Phys. 2009; 74(2):388-91.
• [7]Keall PJ, Colvill E, O’Brien R, Ng JA, Poulsen PR, Eade T et al.. The first clinical implementation of electromagnetic transponder-guided MLC tracking. Med Phys. 2014; 41(2):020702.
• [8]Ng JA, Booth JT, Poulsen PR, Fledelius W, Worm ES, Eade T et al.. Kilovoltage intrafraction monitoring for prostate intensity modulated Arc therapy: first clinical results. Int J Radiat Oncol Biol Phys. 2012; 84(5):e655-61.
• [9]Eade TN, Guo L, Forde E, Vaux K, Vass J, Hunt P et al.. Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy. BJU Int. 2012; 109(11):1655-60.
• [10]Gysen K, Kneebone A, Alfieri F, Guo L, Eade T. Feasibility of and rectal dosimetry improvement with the use of SpaceOAR® hydrogel for dose-escalated prostate cancer radiotherapy. J Med Imaging Radiat Oncol. 2014; 58(4):511-6.
• [11]Santanam L, Malinowski K, Hubenshmidt J, Dimmer S, Mayse ML, Bradley J et al.. Fiducial-based translational localization accuracy of electromagnetic tracking system and on-board kilovoltage imaging system. Int J Radiat Oncol Biol Phys. 2008; 70(3):892-9.
• [12]Keall PJ, Ng JA, O’Brien R, Colvill E, Huang C-Y, Poulsen PR, et al. The first clinical treatment with kilovoltage intrafraction monitoring (KIM): A real-time image guidance method. Med Phys. 2015;42(1):354–8.
• [13]Adamson J, Wu Q. Prostate intrafraction motion assessed by simultaneous kilovoltage fluoroscopy at megavoltage delivery I: Clinical observations and pattern analysis. Int J Radiat Oncol Biol Phys. 2010; 78(5):1563-70.
• [14]Langen KM, Willoughby TR, Meeks SL, Santhanam A, Cunningham A, Levine L et al.. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys. 2008; 71(4):1084-90.
• [15]Li HS, Chetty IJ, Enke CA, Foster RD, Willoughby TR, Kupellian PA et al.. Dosimetric Consequences of Intrafraction Prostate Motion. Int J Radiat Oncol Biol Phys. 2008; 71(3):801-12.
• [16]Cabin RJ, Mitchell RJ. To Bonferroni or not to Bonferroni: when and how are the questions. Bulletin of the Ecological Society of, America; 2000. p. 246–248
• [17]Kron T, Thomas J, Fox C, Thompson A, Owen R, Herschtal A et al.. Intra-fraction prostate displacement in radiotherapy estimated from pre- and post-treatment imaging of patients with implanted fiducial markers. Radiother Oncol. 2010; 95(2):191-7.
• [18]Polat B, Guenther I, Wilbert J, Goebel J, Sweeney RA, Flentje M et al.. Intra-fractional uncertainties in image-guided intensity-modulated radiotherapy (IMRT) of prostate cancer. Strahlenther Onkol. 2008; 184(12):668-73.
• [19]Reggiori G, Mancosu P, Tozzi A, Cantone MC, Castiglioni S, Lattuada P et al.. Cone beam CT pre-and post-daily treatment for assessing geometrical and dosimetric intrafraction variability during radiotherapy of prostate cancer. J Appl Clin Med Phys. 2010; 12(1):3371.
• [20]Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 327(8476):307-10.
• [21]Pinkawa M, Piroth MD, Holy R, Escobar-Corral N, Caffaro M, Djukic V et al.. Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall. Radiother Oncol. 2013; 106(2):220-4.
• [22]Noel C, Parikh PJ, Roy M, Kupelian P, Mahadevan A, Weinstein G et al.. Prediction of intrafraction prostate motion: accuracy of Pre- and post-treatment imaging and intermittent imaging. Int J Radiat Oncol Biol Phys. 2009; 73(3):692-8.
• [23]Kotte ANTJ, Hofman P, Lagendijk JJW, van Vulpen M, van der Heide UA. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2007; 69(2):419-25.
• [24]Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB et al.. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005; 62(2):406-17.
• [25]Oliver M, Ansbacher W, Beckham WA. Comparing planning time, delivery time and plan quality for IMRT, RapidArc and Tomotherapy. J Appl Clin Med Phys. 2009; 10(4):3068.
• [26]Keros L, Bernier V, Aletti P, Marchesi V, Wolf D, Noel A. Qualitative estimation of pelvic organ interactions and their consequences on prostate motion: study on a deceased person. Med Phys. 2006; 33(6):1902-10.